logo
Alpha males are rare among our fellow primates: scientists

Alpha males are rare among our fellow primates: scientists

Yahoo08-07-2025
New research on Monday contradicted the commonly held idea that males dominate females among primates, revealing far more nuanced power dynamics in the relationships of our close relatives.
"For a long time we have had a completely binary view of this issue: we thought that a species was either dominated by males or females -- and that this was a fixed trait," Elise Huchard, a primatologist at the University of Montpellier in France, told AFP.
"Recently, this idea has been challenged by studies showing that the truth is much more complicated," said the lead author of a new study published in the journal PNAS.
The French-German team of researchers combed through scientific literature for interactions between male and female primates that revealed their hierarchical relationships.
These included aggression, threats and signs of dominant or submissive behaviour, such as when one primate spontaneously moved out of the way of another.
Over five years, the team gathered data from 253 populations across 121 primate species, including a range of monkeys, lemurs, tarsiers and lorises.
They found that confrontations between members of the opposite sex were much more frequent than had been previously thought. On average, more than half of these interactions within a group involved a male and a female.
Males clearly dominating females, which was defined as winning more than 90 percent of these confrontations, was only observed in 17 percent of the populations. Among this minority were baboons and chimpanzees, which are the closest living relatives to humans.
Clear female domination was recorded in 13 percent of the primate populations, including lemurs and bonobos.
This meant that for 70 percent of the primates, either males or females could be at the top of the pecking order.
- Battle of the sexes -
When male domination was particularly pronounced, it was usually in a species where males have a clear physical advantage, such as bigger bodies or teeth.
It was also more common among ground-bound species, in which females are less able to run and hide compared to their relatives living in the trees.
Females, meanwhile, tended to dominate over societies when they exerted control over reproduction.
For example, the genitals of female baboons swell when they are ovulating. Males jealously guard females during these few days of their menstrual cycle, making sure that other competitors cannot mate with them.
However in bonobos, this sexual swelling is less obvious.
"Males never know when they are ovulating or not. As a result, (the female bonobos) can mate with whoever they want, whenever they want, much more easily," Huchard said.
Female dominance is also more common when females compete with each other, and when males provide more care for the young.
In these species, females are often solitary or only live in male-female pairs. This means that monogamy is closely linked to female dominance.
Can these results be extrapolated to our own species? There are a great many differences between humans and our fellow primates, Huchard emphasised.
But we would broadly fall into the middle category in which neither males nor females always have strict dominance over the other.
"These results corroborate quite well with what we know about male-female relationships among hunter-gatherers, which were more egalitarian than in the agricultural societies that emerged later" in human history, Huchard said.
ber/dl/giv
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Massive sleep study reveals surprising cost of going to bed late
Massive sleep study reveals surprising cost of going to bed late

Miami Herald

timea day ago

  • Miami Herald

Massive sleep study reveals surprising cost of going to bed late

As an avid Oura user, I'm no stranger to *slightly* obsessing over sleep data. I've tracked my deep sleep, REM cycles, HRV, and recovery scores like a mini scientist in a silk sleep mask. I've timed workouts based on my readiness score. When it comes to the link between sleep and performance, I'm not new here. But even with all that tracking and optimization, this new study got my attention. Researchers looked at millions of nights of sleep-over 6 million to be exact-and what they found was something most of us (myself included) tend to overlook. It's not just about how much you sleep. Related: FDA eliminates 52 food standards in sweeping deregulation move It's about when. And more specifically: what happens when you go to bed later than usual. The impact? Subtle at first. But if you're trying to be consistent with your workouts, boost your energy, or just feel better, those late nights might be holding you back. Even if you're still getting 7 to 8 hours of sleep. That's what makes this study different. Because this time, we're not just talking about sleep duration. We're talking about timing-and how it can affect your body and behavior the very next day. The study, published in PNAS, looked at over 6 million nights of sleep data from nearly 26,000 adults using wearable fitness trackers. Specifically, over 19,000 WHOOP users and nearly 6,000 Fitbit device users. Here's what they found: people who went to bed earlier were more likely to exercise the next day. And the difference? Bigger than you'd think. For example, compared to those who went to sleep around 1 a.m., people who consistently went to bed at 9 p.m. logged 28 more minutes of moderate-to-vigorous physical activity (MVPA) the next day. Even more surprising? People who slept less overall, but went to bed earlier, often exercised more than those who slept longer but went to bed later. In other words, timing beat out total sleep when it came to getting people moving. I spoke with Dr. Mark Czeisler, Resident Physician at Brigham and Women's Hospital and Clinical Fellow at Harvard Medical School, who co-authored the study led by Josh Leota, a Research Fellow at Monash University. Related: These clean food brands are rightfully challenging the FDA He explained why bedtime and not just sleep time matters: "People got the most intense exercise when they preserved their usual sleep amount, but went to bed earlier than they typically do," he said. "That suggests these health behaviors aren't competing with each other. They're best thought of as working in concert." Think about it: if you're staying up late to finish one more episode or scroll TikTok, you could be trading away the energy and motivation you'll need tomorrow. Dr. Czeisler also noted that early sleepers are more likely to get in their workouts before the day gets busy. Morning routines tend to be more reliable-and that consistency matters. While this study tracked people living their normal lives-not under lab conditions-it's truly a big moment for sleep and fitness tech. And it supports something companies like WHOOP, Fitbit, Apple Watch and Oura have been saying for years: when you sleep matters just as much as how much you sleep. The WHOOP data came from users who were already pretty active-averaging 90 minutes of MVPA daily. But the researchers confirmed the same trend in a broader group, using Fitbit data from the NIH's All of Us program. Even people who weren't exercising much still saw a difference. Earlier bedtimes meant more movement the next day. As Dr. Czeisler put it: "The way to guarantee exercise is really to protect the morning. And so going to bed earlier, you know, lends itself to doing that." So if you're trying to get consistent with your workouts, improve your energy, or just build better habits, maybe start by looking at the clock. Going to bed a little earlier might be the simplest, most powerful performance tool you're not using yet. Protect your mornings, people! I know I do... Related: Watch out Fitbit and Apple Watch, Amazon has entered the chat The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

Llamas could help treat schizophrenia: study
Llamas could help treat schizophrenia: study

New York Post

time2 days ago

  • New York Post

Llamas could help treat schizophrenia: study

Talk about a llama-zing discovery. They're known for their fluffy furs and sassy stares, but scientists have discovered that llamas may also be the key to treating schizophrenia. And this isn't even the first time this year that llamas have been at the heart of curing a scary health issue. Advertisement They're known for their fluffy furs and sassy stares, but it turns out llamas may also be the key to treating schizophrenia. Cavan for Adobe – In a mind-blowing new study, French researchers have developed a molecule from llama antibodies that could one day help patients with schizophrenia overcome cognitive deficits — a major hurdle that existing treatments fail to address. Scientists at the Institute of Functional Genomics in Montpellier have engineered what's called a nanobody — a tiny antibody fragment found in camelids like llamas — that can activate a specific glutamate receptor responsible for brain signaling. What's more, this molecule can cross the blood-brain barrier — a major challenge in drug development — and go straight to work on neural receptors when injected via a vein or muscle. Advertisement Researchers tested the llama-derived nanobody in two preclinical models of schizophrenia. Just one injection was enough to boost brainpower in mice, showing a clear and sustained improvement in cognitive function for up to a week. More research will be needed to see if this presents a promising new avenue of treatment for schizophrenia and, if so, whether or not this can be expanded to treat other psychiatric and neurodegenerative diseases. Advertisement The findings were published Wednesday in the journal Nature. Schizophrenia is a chronic mental disorder that affects how people perceive reality, leading to hallucinations, delusions, disorganized thinking and speech, paranoia and time gaps. elnariz – Schizophrenia is a chronic mental disorder that affects how people perceive reality, leading to hallucinations, delusions, disorganized thinking and speech, paranoia and time gaps. More than 200,000 people in the US are living with schizophrenia, for which there is no cure. Advertisement The cause of schizophrenia is still unknown, but research suggests a combination of genetic and environmental factors are likely to encourage its onset, which typically occurs between the ages of 16 and 30. Schizophrenia is primarily treated with antipsychotics, which target some of the more severe symptoms like hallucinations and delusions, but fail to do much for cognitive function. This new study offers hope for repairing cognition, as opposed to simply managing symptoms. 'In humans obviously we don't know [yet], but in mice yes, it is sufficient to treat most deficits of schizophrenia,' paper author and CNRS molecular biologist Jean-Philippe Pin told Newsweek. 'For development as a therapeutic tool, more safety and bioavailability studies are needed. Production of large quantities of high quality must be set up to start human studies. For these two possibilities, either a company takes up our project or we find investors to create a startup company.' Meanwhile, another study published last month found that llamas may also hold the secret weapon to curing COVID — and it's also in their nanobodies. 'This work provides a strong foundation for developing next-generation antibodies that could be vital in combating not only current but also future coronavirus threats,' said Dr. Xavier Saelens, senior author of the study and a principal investigator at the VIB-UGent Center for Medical Biotechnology in Belgium.

Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio
Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio

Yahoo

time3 days ago

  • Yahoo

Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio

In the race to develop next-generation respiratory virus vaccines, French pharmaceutical company Sanofi has agreed to buy Vicebio Ltd., a privately-held biotechnology company headquartered in London, UK. Sanofi said there will be an initial cash payment of $1.15bn (€980 million) for the deal, 'with potential milestone payments of up to $450 million based on development and regulatory achievements'. 'We are excited to join Sanofi', said Emmanuel Hanon, Chief Executive Officer at Vicebio, in a statement. 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realise the potential of our innovative technology." With the acquisition, Sanofi gets Vicebio's early-stage combination vaccine candidate for two respiratory viruses, the respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Respiratory infections, affecting millions globally, often appear as cold-like illnesses that could, in severe cases, lead to pneumonia. In respiratory medication, Sanofi already has several vaccines in its portfolio against flu and RSV prevention; this latest acquisition adds a non-mRNA vaccine to its pipeline. mRNA technology is relatively new for vaccines. It teaches the body how to make a protein that triggers an immune response to protect against a specific virus, instead of using a weakened or inactivated germ to trigger this reaction. With the current deal, Sanofi also gets access to Vicebio's Molecular Clamp technology, which stabilises viral proteins in their native shape, triggering a more effective immune response. This technology is expected to speed up vaccine development and simplify manufacturing and distribution. Related EU pharma chief calls for European Nasdaq to boost biotech innovation Doliprane-maker Sanofi confirms exclusive talks with US firm CD&R 'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation," said Jean-François Toussaint, global head of research and development vaccines at Sanofi. The transaction is expected to close by the end of 2025, and will not have a significant impact on Sanofi's financial guidance for 2025. The pharma giant's share price was down around 0.4% before 11:00 CEST in Paris.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store